Skip to main content
Midas Edge

NRX Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

NRXP$2.380.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statement of Changes in Stockholders’ Equity (Deficit)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ (DEFICIT) EQUITY

(in thousands, except share data)

​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Accumulated Other · ​ · Total
​ · ​ · Preferred Stock · ​ · Series A Preferred Stock · ​ · Common Stock · ​ · Paid-in- · ​ · Accumulated · ​ · Comprehensive · ​ · Stockholders’
​ · ​ · Shares · ​ · Amount · ​ · Shares · ​ · Amount · ​ · Shares · ​ · Amount · ​ · Capital · ​ · Deficit · Income (Loss) · Equity (Deficit)
Balance - December 31, 2021​—​$—​—​$—​58,810,550​$59​$203,990​$(183,243)​$—​$20,806
Common stock and warrants issued in private placement, net of issuance costs of $2,283​—​​—​—​​—​7,824,727​​8​​22,694​​—​​—​​22,702
Common stock issued for consulting services​—​​—​—​​—​6,037​​—​​17​​—​​—​​17
Common stock issued for exercise of stock options​—​​—​—​​—​49,605​​—​​10​​—​​—​​10
Restricted stock awards granted​—​​—​—​​—​1,000,000​​1​​(1)​​—​​—​​—
Retired Earnout Shares​—​​—​—​​—​(1,247,930)​​(1)​​1​​—​​—​​—
Stock-based compensation​—​​—​—​​—​—​​—​​3,628​​—​​—​​3,628
Net loss​—​​—​—​​—​—​​—​​—​​(39,754)​​—​​(39,754)
Balance December 31, 2022​—​$—​—​$—​66,442,989​$67​$230,339​$(222,997)​$—​$7,409
Common stock and warrants issued, net of issuance costs $2,519​—​​—​—​​—​13,536,668​​13​​8,109​​—​​—​​8,122
Preferred stock and warrants issued, net of issuance costs $27​—​​—​3,000,000​​3​—​​—​​1,168​​—​​—​​1,171
Change in fair value of convertible note attributed to credit risk​—​​—​—​​—​—​​—​​—​​—​​(3)​​(3)
Shares issued as repayment of principal and interest for convertible note​—​​—​—​​—​3,264,221​​3​​979​​—​​—​​982
Common stock issued to settle GEM settlement liability​—​​—​—​​—​675,676​​1​​249​​—​​—​​250
Adjustment for deferred offering cost settlement​—​​—​—​​—​—​​—​​99​​—​​—​​99
Stock-based compensation​—​​—​—​​—​—​​—​​387​​—​​—​​387
Net loss​—​​—​—​​—​—​​—​​—​​(30,150)​​—​​(30,150)
Balance - December 31, 2023​—​$—​3,000,000​$3​83,919,554​$84​$241,330​$(253,147)​$(3)​$(11,733)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.